Biosimilars Canada, a national association for the biosimilar medicines industry, is drawing attention to the recent imp…

New drug impacts on private drug plans examined in new report.

Costs grew faster in 2021-2022 than in the previous five years.

Majority of insurers expect increases to continue in the coming three years.

Approximately 25 per cent of drugs making the list are at high risk of shortage in Canada.

Aon survey finds slowing increases in medical plan unit costs.

Drug industry’s growth trends examined, alongside typical distribution methods.

Ontario Drug Benefit recipients who are on an originator biologic will begin to transition to a Health Canada approved b…

Pharmaceutical association says draft guidelines will exacerbate an already unpredictable regulatory environment.

Biologics are putting a strain on private group plans by treating orphan diseases, as well as common diseases, at high c…